Wave Life Sciences (NASDAQ: WVE) announced that its redomiciliation from Singapore to Delaware is expected to become effective after the close of trading on Aug. 7, 2026, following approval from the High Court of the Republic of Singapore.

The High Court of the Republic of Singapore approved the redomiciliation on July 14, 2026, under a scheme of arrangement pursuant to Section 210 of the Companies Act 1967 of Singapore. The process will be completed upon filing of the court order with the Accounting and Corporate Regulatory Authority of Singapore.

The company had previously obtained the required shareholder approvals for the transaction, which changes the parent company of the group from a Singapore-incorporated entity to a Delaware corporation.

Wave Life Sciences also stated it plans to file a series of documents with the U.S. Securities and Exchange Commission after market close on the same day the redomiciliation takes effect.